Form 4: MAIA Biotechnology Executive Reports Stock Options

MAIA Biotechnology, Inc. reports that Head of Finance, Jeffrey C. Himmelreich, acquired 60,000 stock options on May 29, 2026.

Summary

• Jeffrey C. Himmelreich, Head of Finance at MAIA Biotechnology, Inc., was granted 60,000 stock options on May 29, 2026.
• These options have an exercise price of $1.39 and are exercisable starting May 29, 2036.
• The options are part of the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan.
• The options vest over a four-year period, with 25% vesting on the first anniversary of the grant date and the remainder vesting monthly over the subsequent 36 months.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard executive compensation event without providing new financial or operational information about the company.

Positives

• Grant of stock options to a key executive, indicating potential alignment of management interests with shareholder value.
• The options are granted under an existing equity incentive plan, suggesting a structured approach to compensation.
• The vesting schedule is spread over four years, encouraging long-term commitment from the executive.

Negatives

• The filing does not provide details on the company's financial performance or operational status, making it difficult to assess the intrinsic value of the options.
• The exercise date is significantly in the future (May 29, 2036), meaning the immediate impact on the company's financial health is minimal.

Risks

• The value of the stock options is subject to the future performance of MAIA Biotechnology, Inc.'s stock price.
• If the company's stock price does not exceed the exercise price of $1.39 by the expiration date, the options may expire worthless.
• The long vesting period means that the executive's continued employment and commitment are prerequisites for full benefit from the options.

Future Outlook

The filing primarily concerns the grant of stock options and does not contain forward-looking financial guidance or projections for MAIA Biotechnology, Inc.

Management Comments

• The stock options were granted pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan.
• The options represent the right to buy shares of common stock.
• The options vest on a 4-year schedule, with 25% vesting on the first anniversary of the grant and the remainder vesting ratably monthly thereafter for 36 months.

Industry Context

StockSavvy.ai notes that the granting of stock options to executives is a common practice in the biotechnology sector to incentivize performance and retain talent, especially in companies with long development cycles.

Stakeholder Impact

• Shareholders: The grant of options could lead to future dilution if exercised, but also aligns executive incentives with long-term stock performance.
• Employees: The existence of an equity incentive plan suggests a culture of potential equity participation for employees.
• Management: The executive receives potential future financial benefit tied to company performance.

Next Steps

• The executive will receive vested options over a four-year period.
• The options can be exercised on or after May 29, 2036, subject to the company's stock performance.

Key Dates

Keywords

MAIA Biotechnology, Form 4, Stock Options, Executive Compensation, Equity Incentive Plan, Jeffrey C. Himmelreich, SEC Filing, Insider Trading